Industry News: LGC’s ValuPanel Reagents help public laboratories detect SARS-CoV-2 and influenza
Each line of ValuPanel Reagents consists of separately delivered probes and primers, which allow assay flexibility and sizes that can help facilitate scale-up
26 Apr 2021
LGC, Biosearch Technologies has announced the release of a new set of ValuPanel™ Reagents to help the efforts of public health laboratories to detect SARS-CoV-2, influenza A, and influenza B.
The CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex ValuPanel Reagents - which are for research use only and not for use in diagnostic procedures - consists of probes and primers for multiplex RT-PCR detection and allows discrimination of SARS-CoV-2, influenza A, and influenza B from a single patient sample.